{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T19:57:59Z","timestamp":1774641479704,"version":"3.50.1"},"reference-count":169,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"am","delay-in-days":305,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003768","name":"Universit\u00e9 de Strasbourg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003768","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["691119 \u2014 EU4HIVCURE \u2014 H2020-MSCA-RISE-2015"],"award-info":[{"award-number":["691119 \u2014 EU4HIVCURE \u2014 H2020-MSCA-RISE-2015"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["H2020-MSCA-RISE-2015"],"award-info":[{"award-number":["H2020-MSCA-RISE-2015"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.bcp.2021.114893","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T02:34:31Z","timestamp":1640658871000},"page":"114893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Suicide gene therapy in cancer and HIV-1 infection: An alternative to conventional treatments"],"prefix":"10.1016","volume":"197","author":[{"given":"Sepideh","family":"Saeb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne Van","family":"Assche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Loustau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mentine","family":"Wallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2021.114893_b0005","unstructured":"Cancer. Available from: <https:\/\/www.who.int\/health-topics\/cancer#tab=tab_1>."},{"key":"10.1016\/j.bcp.2021.114893_b0010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5603\/MRJ.a2019.0016","article-title":"Limitations of molecularly targeted therapy","volume":"4","author":"Balik","year":"2019","journal-title":"Med. Res. J."},{"key":"10.1016\/j.bcp.2021.114893_b0015","doi-asserted-by":"crossref","unstructured":"I.-K. Choi et al., Strategies to increase drug penetration in solid tumors. (2013). doi: 10.3389\/fonc.2013.00193.","DOI":"10.3389\/fonc.2013.00193"},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4599","key":"10.1016\/j.bcp.2021.114893_b0025","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barr\u00e9-Sinoussi","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.bcp.2021.114893_b0030","unstructured":"UNAIDS report on the global AIDS epidemic shows that 2020 targets will not be met because of deeply unequal success; COVID-19 risks blowing HIV progress way off course | UNAIDS. Available from: <https:\/\/www.unaids.org\/en\/resources\/presscentre\/pressreleaseandstatementarchive\/2020\/july\/20200706_global-aids-report>."},{"issue":"11","key":"10.1016\/j.bcp.2021.114893_b0035","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bcp.2021.114893_b0040","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team","volume":"337","author":"Hammer","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bcp.2021.114893_b0045","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/QAD.0000000000000243","article-title":"Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy","volume":"28","author":"May","year":"2014","journal-title":"AIDS"},{"issue":"26","key":"10.1016\/j.bcp.2021.114893_b0050","doi-asserted-by":"crossref","first-page":"15109","DOI":"10.1073\/pnas.96.26.15109","article-title":"HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression","volume":"96","author":"Davey","year":"1999","journal-title":"PNAS"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2021.114893_b0055","first-page":"S21","article-title":"Impact of nucleoside reverse transcriptase inhibitors on coronary heart disease","volume":"15","author":"Mallon","year":"2014","journal-title":"Rev. Cardiovasc. Med."},{"issue":"6","key":"10.1016\/j.bcp.2021.114893_b0060","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/14787210.2016.1184570","article-title":"Protecting bone in long-term HIV positive patients receiving antiretrovirals","volume":"14","author":"McGinty","year":"2016","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"10.1016\/j.bcp.2021.114893_b0065","first-page":"1","article-title":"Predictors of longitudinal change in bone mineral density in a cohort of HIV-positive and negative subjects","author":"Tinago","year":"2017","journal-title":"AIDS (London, England)"},{"issue":"5","key":"10.1016\/j.bcp.2021.114893_b0070","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/QAD.0b013e32835cb747","article-title":"Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment","volume":"27","author":"Lapadula","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2021.114893_b0075","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.antiviral.2015.03.002","article-title":"Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort","volume":"117","author":"Pacheco","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2021.114893_b0080","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1097\/QAD.0b013e3283174636","article-title":"The role of HIV in serious diseases other than AIDS","volume":"22","author":"Phillips","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2021.114893_b0085","unstructured":"M.J. Glesby, Cardiovascular complications of HIV infection, Topics Antiviral Med. 24, 127\u2013131."},{"key":"10.1016\/j.bcp.2021.114893_b0090","unstructured":"C.M. Wyatt, Kidney disease and HIV infection, Topics Antiviral Med. 25, 13\u201316."},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0095","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/COH.0000000000000230","article-title":"Residual inflammation and viral reservoirs: alliance against an HIV cure","volume":"11","author":"Massanella","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.bcp.2021.114893_b0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1742-4690-10-67","article-title":"HIV-1 transcription and latency: an update","volume":"10","author":"Van Lint","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.bcp.2021.114893_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2019.03060","article-title":"Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs","volume":"10","author":"Ait-Ammar","year":"2020","journal-title":"Front. Microbiol."},{"issue":"4","key":"10.1016\/j.bcp.2021.114893_b0110","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/tan.12867","article-title":"Barriers to HIV cure","volume":"88","author":"Stein","year":"2016","journal-title":"HLA"},{"key":"10.1016\/j.bcp.2021.114893_b0115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12977-016-0323-4","article-title":"Are T cells the only HIV-1 reservoir?","volume":"13","author":"Kandathil","year":"2016","journal-title":"Retrovirology"},{"key":"10.1016\/j.bcp.2021.114893_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00397","article-title":"Targeting the brain reservoirs: toward an HIV cure","volume":"7","author":"Marban","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2021.114893_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2019.00362","article-title":"Microglial cells: the main HIV-1 reservoir in the brain","volume":"9","author":"Wallet","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"9","key":"10.1016\/j.bcp.2021.114893_b0130","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2174\/1381612822666151221150733","article-title":"Evolving drug delivery strategies to overcome the blood brain barrier","volume":"22","author":"Hersh","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jgm.2698","article-title":"Gene therapy clinical trials worldwide to 2012 - an update","volume":"15","author":"Ginn","year":"2013","journal-title":"J. Gene Med."},{"key":"10.1016\/j.bcp.2021.114893_b0140","first-page":"1464","article-title":"Killing effect of coexpressing cytosine deaminase and thymidine kinase on rat vascular smooth muscle cells","volume":"117","author":"Cao","year":"2004","journal-title":"Chin. Med. J."},{"issue":"7","key":"10.1016\/j.bcp.2021.114893_b0145","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.cgt.7700825","article-title":"Development of an inducible suicide gene system based on human caspase 8","volume":"12","author":"Carlotti","year":"2005","journal-title":"Cancer Gene Ther."},{"issue":"7","key":"10.1016\/j.bcp.2021.114893_b0150","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.mt.6300190","article-title":"The suicide gene therapy challenge: how to improve a successful gene therapy approach","volume":"15","author":"Bonini","year":"2007","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2021.114893_b0155","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/pharmaceutics11060255","article-title":"Eradication of human immunodeficiency virus type-1 (HIV-1)-infected cells","volume":"11","author":"D\u00fczg\u00fcne\u015f","year":"2019","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0160","doi-asserted-by":"crossref","first-page":"071","DOI":"10.1385\/MB:30:1:071","article-title":"Introduction to the background, principles, and state of the art in suicide gene therapy","volume":"30","author":"Niculescu-Duvaz","year":"2005","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.bcp.2021.114893_b0165","first-page":"5276","article-title":"Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy","volume":"46","author":"Fl","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2021.114893_b0170","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2015.05.009","article-title":"Progress and problems with the use of suicide genes for targeted cancer therapy","volume":"99","author":"Karjoo","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0175","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.canlet.2012.05.023","article-title":"Suicide gene therapy in cancer: where do we stand now?","volume":"324","author":"Duarte","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2021.114893_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.605380","article-title":"Strategies for targeting gene therapy in cancer cells with tumor-specific promoters","volume":"10","author":"Monta\u00f1o-Samaniego","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2021.114893_b0185","doi-asserted-by":"crossref","unstructured":"A. Di Stasi et al., Inducible apoptosis as a safety switch for adoptive cell therapy, (2011). doi: 10.1056\/NEJMoa1106152.","DOI":"10.1056\/NEJMoa1106152"},{"issue":"3","key":"10.1016\/j.bcp.2021.114893_b0190","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0002-9378(97)70149-2","article-title":"In vitro expression of the diphtheria toxin A-chain gene under the control of human chorionic gonadotropin gene promoters as a means of directing toxicity to ovarian cancer cell lines","volume":"177","author":"Lidor","year":"1997","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0195","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s002030050300","article-title":"Staphylococcal alpha-toxin, streptolysin-O, and Escherichia coli hemolysin: prototypes of pore-forming bacterial cytolysins","volume":"165","author":"Bhakdi","year":"1996","journal-title":"Arch. Microbiol."},{"key":"10.1016\/j.bcp.2021.114893_b0200","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-4939-2727-2_5","article-title":"Oncoleaking: Use of the pore-forming Clostridium perfringens enterotoxin (CPE) for suicide gene therapy jessica pahle1","volume":"1317","author":"Pahle","year":"2015","journal-title":"Methods Mol. Biol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114893_b0205","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Leading edge review hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bcp.2021.114893_b0210","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s11912-012-0259-3","article-title":"HPV vaccination and cervical cancer","volume":"14","author":"Szarewski","year":"2012","journal-title":"Curr. Oncol. Rep."},{"issue":"i3","key":"10.1016\/j.bcp.2021.114893_b0215","doi-asserted-by":"crossref","first-page":"138","DOI":"10.25100\/cm.v48i3.2997","article-title":"Immunotherapy and gene therapy as novel treatments for cancer","volume":"48","author":"Rangel-Sosa","year":"2017","journal-title":"Colombia Med. (Cali, Colombia)"},{"key":"10.1016\/j.bcp.2021.114893_b0220","doi-asserted-by":"crossref","first-page":"13343","DOI":"10.3748\/wjg.v20.i37.13343","article-title":"Gene therapy in pancreatic cancer","volume":"20","author":"Liu","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114893_b0225","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3390\/ijms18061231","article-title":"Gene therapy for pancreatic cancer: specificity, issues and hopes","volume":"18","author":"Rouanet","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2021.114893_b0230","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3748\/wjg.v10.i3.400","article-title":"Herpes simplex virus thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancer","volume":"10","author":"Wang","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bcp.2021.114893_b0235","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/1521-2254(200009\/10)2:5<361::AID-JGM125>3.0.CO;2-7","article-title":"Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer","volume":"2","author":"M\u00e4kinen","year":"2000","journal-title":"J. Gene Med."},{"issue":"4","key":"10.1016\/j.bcp.2021.114893_b0240","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.gt.3300846","article-title":"Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene","volume":"6","author":"Carri\u00f3","year":"1999","journal-title":"Gene Ther."},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0245","first-page":"e21","article-title":"Retrovirus-mediated herpes simplex virus thymidine kinase gene transfer in pancreatic cancer cell lines: an incomplete antitumor effect","volume":"25","author":"Greco","year":"2002","journal-title":"Nursing"},{"issue":"9","key":"10.1016\/j.bcp.2021.114893_b0250","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ejso.2003.08.001","article-title":"Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model","volume":"29","author":"Fogar","year":"2003","journal-title":"Eur. J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0255","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/jsre.1997.5051","article-title":"In VivoAdenoviral-mediated gene transfer in the treatment of pancreatic cancer","volume":"69","author":"Evoy","year":"1997","journal-title":"J. Surg. Res."},{"issue":"9","key":"10.1016\/j.bcp.2021.114893_b0260","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1158\/1535-7163.MCT-08-0347","article-title":"Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene","volume":"7","author":"Kaliberova","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2021.114893_b0265","first-page":"461","article-title":"Virus-directed enzyme prodrug therapy using CB1954","volume":"14","author":"Grove","year":"1999","journal-title":"Anticancer Drug Des."},{"key":"10.1016\/j.bcp.2021.114893_b0270","first-page":"229","article-title":"Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene","volume":"4","author":"Green","year":"1997","journal-title":"Cancer Gene Ther."},{"issue":"6","key":"10.1016\/j.bcp.2021.114893_b0275","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/(SICI)1097-0215(20000615)86:6<848::AID-IJC14>3.0.CO;2-B","article-title":"Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. Coli nitroreductase","volume":"86","author":"Weedon","year":"2000","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2021.114893_b0280","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.gt.3300744","article-title":"Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. Coli nitroreductase and CB1954","volume":"5","author":"McNeish","year":"1998","journal-title":"Gene Ther."},{"issue":"7","key":"10.1016\/j.bcp.2021.114893_b0285","doi-asserted-by":"crossref","first-page":"e40611","DOI":"10.1371\/journal.pone.0040611","article-title":"Evaluation of a gene-directed enzyme-product therapy (GDEPT) in human pancreatic tumor cells and their use as in vivo models for pancreatic cancer","volume":"7","author":"Hlavaty","year":"2012","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0290","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/jgm.247","article-title":"Intratumoral activation of cyclophosphamide by retroviral transfer of the cytochrome P450 2B1 in a pancreatic tumor model. Combination with the HSVtk\/GCV system: CYP2B1\/CPA Sensitizes Pancreatic Tumor Cells","volume":"4","author":"Carri\u00f3","year":"2002","journal-title":"J. Gene Med."},{"issue":"3","key":"10.1016\/j.bcp.2021.114893_b0295","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3390\/pharmaceutics6030447","article-title":"Encapsulated cells expressing a chemotherapeutic activating enzyme allow the targeting of subtoxic chemotherapy and are safe and efficacious: data from two clinical trials in pancreatic cancer","volume":"6","author":"L\u00f6hr","year":"2014","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.bcp.2021.114893_b0300","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1541-7786.MCR-14-0199","article-title":"MUC1 promoter-driven DTA as a targeted therapeutic strategy against pancreatic cancer","volume":"13","author":"Tholey","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bcp.2021.114893_b0305","doi-asserted-by":"crossref","unstructured":"J. Pahle, W. Walther, Bacterial toxins for oncoleaking suicidal cancer gene therapy, in: Recent Results in Cancer Research, vol. 209, Springer New York LLC, 2016, pp. 95\u2013110.","DOI":"10.1007\/978-3-319-42934-2_7"},{"key":"10.1016\/j.bcp.2021.114893_b0310","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3390\/toxins2071595","article-title":"Specificity of interaction between clostridium perfringens enterotoxin and claudin-family tight junction proteins","volume":"2","author":"Mitchell","year":"2010","journal-title":"Toxins"},{"key":"10.1016\/j.bcp.2021.114893_b0315","doi-asserted-by":"crossref","DOI":"10.3390\/toxins8030073","article-title":"Clostridium perfringens enterotoxin: action, genetics, and translational applications","volume":"8","author":"Freedman","year":"2016","journal-title":"Toxins"},{"issue":"5","key":"10.1016\/j.bcp.2021.114893_b0320","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0002-9440(10)63721-2","article-title":"Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4","volume":"164","author":"Kominsky","year":"2004","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114893_b0325","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/gast.2001.27124","article-title":"Claudin-4: a new target for pancreatic cancer treatment using clostridium perfringens enterotoxin","volume":"121","author":"Michl","year":"2001","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bcp.2021.114893_b0330","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/gt.2011.136","article-title":"Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors","volume":"19","author":"Walther","year":"2012","journal-title":"Gene Ther."},{"issue":"4","key":"10.1016\/j.bcp.2021.114893_b0335","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/jcm10040566","article-title":"The state-of-the-art of phase II\/III clinical trials for targeted pancreatic cancer therapies","volume":"10","author":"Garcia-Sampedro","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2021.114893_b0340","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.571951","article-title":"Microglia-centered combinatorial strategies against glioblastoma","volume":"11","author":"Martins","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2021.114893_b0345","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40478-021-01156-z","article-title":"Macrophages and microglia: the cerberus of glioblastoma","volume":"9","author":"Buonfiglioli","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0350","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.bcp.2021.114893_b0355","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuron.2019.08.028","article-title":"Microglia\/brain macrophages as central drivers of brain tumor pathobiology","volume":"104","author":"Gutmann","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2021.114893_b0360","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bcp.2018.12.002","article-title":"Targeting the DNA-PK complex: its rationale use in cancer and HIV-1 infection","volume":"160","author":"Schwartz","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0365","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2052-8426-2-21","article-title":"Gene therapy for malignant glioma","volume":"2","author":"Okura","year":"2014","journal-title":"Mol. Cell Ther."},{"issue":"5063","key":"10.1016\/j.bcp.2021.114893_b0370","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1126\/science.1317968","article-title":"In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors","volume":"256","author":"Culver","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.bcp.2021.114893_b0375","article-title":"In Situ Retroviral-mediated gene transfer for the treatment of brain tumors in rats","volume":"53","author":"Ram","year":"1993","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2021.114893_b0380","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1023\/B:NEON.0000003588.18644.9c","article-title":"Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I\/II multi-institutional trial","volume":"65","author":"Prados","year":"2003","journal-title":"J. Neurooncol."},{"issue":"17","key":"10.1016\/j.bcp.2021.114893_b0385","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1089\/104303400750038499","article-title":"A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme","volume":"11","author":"Rainov","year":"2000","journal-title":"Hum. Gene Ther."},{"issue":"3","key":"10.1016\/j.bcp.2021.114893_b0390","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1023\/B:NEON.0000003657.95085.56","article-title":"Adenovirus\/herpes simplex-thymidine kinase\/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas","volume":"65","author":"Germano","year":"2003","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.bcp.2021.114893_b0395","article-title":"Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects","volume":"2","author":"Hossain","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"issue":"4","key":"10.1016\/j.bcp.2021.114893_b0400","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.18632\/oncotarget.6737","article-title":"Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma","volume":"7","author":"Ji","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.bcp.2021.114893_b0405","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1470-2045(13)70274-2","article-title":"Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial","volume":"14","author":"Westphal","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2021.114893_b0410","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/neuonc\/noz060","article-title":"Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma","volume":"21","author":"Hossain","year":"2019","journal-title":"Neuro-Oncology"},{"issue":"8","key":"10.1016\/j.bcp.2021.114893_b0415","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/neuonc\/now002","article-title":"Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma","volume":"18","author":"Wheeler","year":"2016","journal-title":"Neuro-Oncology"},{"issue":"19","key":"10.1016\/j.bcp.2021.114893_b0420","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-09-1087","article-title":"Antiglioma immunological memory in response to conditional cytotoxic\/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression","volume":"15","author":"Ghulam Muhammad","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.bcp.2021.114893_b0425","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1158\/0008-5472.CAN-04-3434","article-title":"Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model","volume":"65","author":"Ali","year":"2005","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0430","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/jnnp-2012-302946","article-title":"The art of gene therapy for glioma: a review of the challenging road to the bedside","volume":"84","author":"Tobias","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0435","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/neuonc\/nor199","article-title":"Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector","volume":"14","author":"Ostertag","year":"2012","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bcp.2021.114893_b0440","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/neuonc\/nox037","article-title":"Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model","volume":"19","author":"Mitchell","year":"2017","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bcp.2021.114893_b0445","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/neuonc\/noy075","article-title":"Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC","volume":"20","author":"Cloughesy","year":"2018","journal-title":"Neuro-Oncology"},{"issue":"12","key":"10.1016\/j.bcp.2021.114893_b0450","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jamaoncol.2020.3161","article-title":"Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial","volume":"6","author":"Cloughesy","year":"2020","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0455","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/10430340050016175","article-title":"Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine","volume":"11","author":"Adachi","year":"2000","journal-title":"Hum. Gene Ther."},{"issue":"10","key":"10.1016\/j.bcp.2021.114893_b0460","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.cgt.7700506","article-title":"Combined radiation and gene therapy for brain tumors with adenovirus-mediated transfer of cytosine deaminase and uracil phosphoribosyltransferase genes","volume":"9","author":"Kambara","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bcp.2021.114893_b0465","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.621831","article-title":"Current approaches for glioma gene therapy and virotherapy","volume":"14","author":"Banerjee","year":"2021","journal-title":"Front. Mol. Neurosci."},{"issue":"46","key":"10.1016\/j.bcp.2021.114893_b0470","doi-asserted-by":"crossref","first-page":"20021","DOI":"10.1073\/pnas.1008261107","article-title":"Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics","volume":"107","author":"Candolfi","year":"2010","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2021.114893_b0475","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noz175.042","article-title":"ATIM-44. A phase I first-in-human trial of two adenoviral vectors expressing HSV1-TK and FLT3L for treating newly diagnosed resectable malignant glioma: therapeutic reprogramming of the brain immune system","volume":"21","author":"Lowenstein","year":"2019","journal-title":"Neuro-Oncology"},{"issue":"10","key":"10.1016\/j.bcp.2021.114893_b0480","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/gt.2008.41","article-title":"Stem and progenitor cell-mediated tumor selective gene therapy","volume":"15","author":"Aboody","year":"2008","journal-title":"Gene Ther."},{"issue":"23","key":"10.1016\/j.bcp.2021.114893_b0485","doi-asserted-by":"crossref","first-page":"12846","DOI":"10.1073\/pnas.97.23.12846","article-title":"Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas","volume":"97","author":"Aboody","year":"2000","journal-title":"PNAS"},{"issue":"12","key":"10.1016\/j.bcp.2021.114893_b0490","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1158\/1078-0432.CCR-16-1518","article-title":"Neural stem cell-based anticancer gene therapy: A first-in-human study in recurrent high-grade glioma patients","volume":"23","author":"Portnow","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2021.114893_b0495","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/CIRCRESAHA.111.256149","article-title":"Steps toward safe cell therapy using induced pluripotent stem cells","volume":"112","author":"Okano","year":"2013","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0500","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10593","article-title":"Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma","volume":"7","author":"Bag\u00f3","year":"2016","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.bcp.2021.114893_b0505","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.gt.3302276","article-title":"Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model","volume":"11","author":"Nakamura","year":"2004","journal-title":"Gene Ther."},{"issue":"6","key":"10.1016\/j.bcp.2021.114893_b0510","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/ijc.28455","article-title":"Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario","volume":"134","author":"Altaner","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0515","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/v12020188","article-title":"Reduce and control: a combinatorial strategy for achieving sustained HIV remissions in the absence of antiretroviral therapy","volume":"12","author":"Schwarzer","year":"2020","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.bcp.2021.114893_b0520","doi-asserted-by":"crossref","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","article-title":"Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study","volume":"9","author":"S\u00e1ez-Ciri\u00f3n","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2021.114893_b0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/microorganisms9020228","article-title":"Hiv-1 entry and prospects for protecting against infection","volume":"9","author":"Bruxelle","year":"2021","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0530","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1073\/pnas.89.1.182","article-title":"Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population","volume":"89","author":"Caruso","year":"1992","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0535","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/hum.1991.2.1-53","article-title":"Activation of a diphtheria toxin a gene by expression of human immunodeficiency virus-1 tat and rev proteins in transfected cells","volume":"2","author":"Harrison","year":"1991","journal-title":"Hum. Gene Ther."},{"issue":"11","key":"10.1016\/j.bcp.2021.114893_b0540","doi-asserted-by":"crossref","first-page":"e26894","DOI":"10.1371\/journal.pone.0026894","article-title":"Genome-wide binding map of the HIV-1 Tat protein to the human genome","volume":"6","author":"Marban","year":"2011","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.bcp.2021.114893_b0545","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.1992.3.5-461","article-title":"Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin a chain gene","volume":"3","author":"Harrison","year":"1992","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0550","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0041-0101(93)90360-U","article-title":"Effects of enhancer mutations on the expression of human immunodeficiency virus 1-regulated luciferase and diphtheria toxin A chain genes in transfected cells","volume":"31","author":"Harrison","year":"1993","journal-title":"Toxicon"},{"issue":"11","key":"10.1016\/j.bcp.2021.114893_b0555","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1089\/hum.1995.6.11-1437","article-title":"HIV-regulated diphtheria toxin A chain gene confers long-term protection against HIV type 1 infection in the human promonocytic cell line U937","volume":"6","author":"Dinges","year":"1995","journal-title":"Hum. Gene Ther."},{"issue":"6","key":"10.1016\/j.bcp.2021.114893_b0560","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/hum.1993.4.6-741","article-title":"Long-term inhibition of clinical and laboratory human immunodeficiency virus strains in human T-cell lines containing an HIV-regulated diphtheria toxin A chain gene","volume":"4","author":"Curiel","year":"1993","journal-title":"Hum. Gene Ther."},{"issue":"3","key":"10.1016\/j.bcp.2021.114893_b0565","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1089\/hum.1992.3.3-319","article-title":"Phase I study of cellular adoptive immunotherapy using genetically modified CD8 + HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. Fred Hutchinson Cancer Research Center and the University of Washington","volume":"3","author":"Riddell","year":"1992","journal-title":"Hum. Gene Ther."},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0570","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-4889(96)00176-0","article-title":"Cationic liposome-mediated expression of HIV-regulated luciferase and diphtheria toxin a genes in HeLa cells infected with or expressing HIV","volume":"1356","author":"Konopka","year":"1997","journal-title":"Biochim. Biophys. Acta - Molecular Cell Res."},{"key":"10.1016\/j.bcp.2021.114893_b0575","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/10430349950019237","article-title":"Inhibition of human immunodeficiency virus type 1 by Tat\/Rev-regulated expression of cytosine deaminase, interferon \u03b12, or diphtheria toxin compared with inhibition by transdominant Rev","volume":"10","author":"Ragheb","year":"1999","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0580","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1128\/jvi.69.1.110-121.1995","article-title":"Inhibition of human immunodeficiency virus type 1 replication by a Tat-activated, transduced interferon gene: targeted expression to human immunodeficiency virus type 1-infected cells","volume":"69","author":"Su","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2021.114893_b0585","first-page":"402","article-title":"A gene therapy approach to eliminate HIV-1-infected cells","volume":"40","author":"Gebremedhin","year":"2012","journal-title":"J. California Dental Assoc."},{"issue":"5","key":"10.1016\/j.bcp.2021.114893_b0590","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1089\/hum.2015.126","article-title":"Conditional cytotoxic anti-HIV gene therapy for selectable cell modification","volume":"27","author":"Garg","year":"2016","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0595","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6750-11-4","article-title":"A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication","volume":"11","author":"Huelsmann","year":"2011","journal-title":"BMC Biotech."},{"key":"10.1016\/j.bcp.2021.114893_b0600","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.omtn.2017.03.004","article-title":"Expression of herpes simplex virus thymidine kinase\/ganciclovir by RNA trans-splicing induces selective killing of hiv-producing cells","volume":"7","author":"Ingemarsdotter","year":"2017","journal-title":"Mol. Ther. Nucl. Acids"},{"issue":"8","key":"10.1016\/j.bcp.2021.114893_b0605","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jid.2012.101","article-title":"Spliceosome-mediated trans-splicing","volume":"132","author":"Wally","year":"2012","journal-title":"J. Invest. Dermatol."},{"issue":"1-2","key":"10.1016\/j.bcp.2021.114893_b0610","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jbiotec.2012.01.006","article-title":"Selective regression of cancer cells expressing a splicing variant of AIMP2 through targeted RNA replacement by trans-splicing ribozyme","volume":"158","author":"Won","year":"2012","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.bcp.2021.114893_b0615","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1016\/j.febslet.2006.08.021","article-title":"Cancer-selective induction of cytotoxicity by tissue-specific expression of targeted trans-splicing ribozyme","volume":"580","author":"Ms","year":"2006","journal-title":"FEBS Lett."},{"issue":"10","key":"10.1016\/j.bcp.2021.114893_b0620","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0625","article-title":"HIV-1 CCR5 gene therapy will fail unless it is combined with a suicide gene","volume":"5","author":"Pandit","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0630","doi-asserted-by":"crossref","DOI":"10.1186\/s12985-021-01501-7","article-title":"Combination gene therapy for HIV using a conditional suicidal gene with CCR5 knockout","volume":"18","author":"Mehmetoglu-Gurbuz","year":"2021","journal-title":"Virol. J."},{"issue":"3","key":"10.1016\/j.bcp.2021.114893_b0635","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.antiviral.2006.06.010","article-title":"StpC-based gene therapy targeting latent reservoirs of HIV-1","volume":"72","author":"Turner","year":"2006","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0640","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.virol.2004.03.021","article-title":"Herpesvirus saimiri-encoded proteins Tip and StpC modulate human immunodeficiency virus type 1 replication in T-cell lines and lymphocytes independently of viral tropism","volume":"324","author":"Raymond","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.bcp.2021.114893_b0645","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/157016207779316314","article-title":"Herpesvirus saimiri terminal membrane proteins modulate HIV-1 replication by altering Nef and Tat functions","volume":"5","author":"Raymond","year":"2006","journal-title":"Curr. HIV Res."},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0650","doi-asserted-by":"crossref","DOI":"10.1186\/1742-4690-5-36","article-title":"Selective killing of HIV-1-positive macrophages and T cells by the Rev-dependent lentivirus carrying anthrolysin O from Bacillus anthracis","volume":"5","author":"Young","year":"2008","journal-title":"Retrovirology"},{"issue":"9","key":"10.1016\/j.bcp.2021.114893_b0655","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/gt.2010.53","article-title":"Development of a nonintegrating Rev-dependent lentiviral vector carrying diphtheria toxin A chain and human TRAF6 to target HIV reservoirs","volume":"17","author":"Wang","year":"2010","journal-title":"Gene Ther."},{"issue":"7-8","key":"10.1016\/j.bcp.2021.114893_b0660","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41434-019-0085-4","article-title":"AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy","volume":"26","author":"Pattali","year":"2019","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0665","doi-asserted-by":"crossref","DOI":"10.1186\/s12985-021-01584-2","article-title":"Brain HIV-1 latently-infected reservoirs targeted by the suicide gene strategy","volume":"18","author":"Saeb","year":"2021","journal-title":"Virol. J."},{"issue":"6","key":"10.1016\/j.bcp.2021.114893_b0670","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40495-016-0073-y","article-title":"Enzyme\/prodrug systems for cancer gene therapy","volume":"2","author":"Malekshah","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"issue":"7-8","key":"10.1016\/j.bcp.2021.114893_b0675","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.addr.2009.03.013","article-title":"Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis","volume":"61","author":"Dorer","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0680","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/mt.2009.262","article-title":"A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors","volume":"18","author":"Nemunaitis","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2021.114893_b0685","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jconrel.2021.03.029","article-title":"BBB-crossing adeno-associated virus vector: An excellent gene delivery tool for CNS disease treatment","volume":"333","author":"Chen","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2021.114893_b0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12121216","article-title":"Current status and challenges associated with CNS-targeted gene delivery across the BBB","volume":"12","author":"Kimura","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bcp.2021.114893_b0695","doi-asserted-by":"crossref","first-page":"188458","DOI":"10.1016\/j.bbcan.2020.188458","article-title":"Pre-clinical tumor models of primary brain tumors: Challenges and opportunities","volume":"1875","author":"Akter","year":"2021","journal-title":"Biochim. Biophys. Acta (BBA) \u2013 Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0700","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ccell.2020.01.004","article-title":"Comparative molecular life history of spontaneous canine and human gliomas","volume":"37","author":"Amin","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2021.114893_b0705","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/vco.12152","article-title":"Canine brain tumours: a model for the human disease?","volume":"15","author":"Hicks","year":"2017","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.bcp.2021.114893_b0710","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13051087","article-title":"Cellular and molecular mechanisms underlying Glioblastoma and Zebrafish models for the discovery of new treatments","volume":"13","author":"Reimunde","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2021.114893_b0715","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.16578","article-title":"Organoid models of the tumor microenvironment and their applications","volume":"25","author":"Xia","year":"2021","journal-title":"J. Cellular Mol. Med."},{"issue":"4","key":"10.1016\/j.bcp.2021.114893_b0720","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/hum.2016.022","article-title":"Epithelial junction opener improves oncolytic adenovirus therapy in mouse tumor models","volume":"27","author":"Yumul","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bcp.2021.114893_b0725","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00193","article-title":"Strategies to increase drug penetration in solid tumors","volume":"3","author":"Choi","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2021.114893_b0730","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02251","article-title":"The quest for cellular markers of HIV reservoirs: any color you like","volume":"10","author":"Darcis","year":"2019","journal-title":"Front. Immunol."},{"issue":"7646","key":"10.1016\/j.bcp.2021.114893_b0735","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature21710","article-title":"CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses","volume":"543","author":"Descours","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2021.114893_b0740","article-title":"Therapeutic strategies of recurrent glioblastoma and its molecular pathways \u2018Lock up the beast\u2019","volume":"15","author":"Sm","year":"2021","journal-title":"Ecancermedicalscience"},{"issue":"13","key":"10.1016\/j.bcp.2021.114893_b0745","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.3390\/cancers13133152","article-title":"A systems approach to brain tumor treatment","volume":"13","author":"Park","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2021.114893_b0750","article-title":"Systematic characterization of extracellular glycoproteins using mass spectrometry","author":"Sun","year":"2021","journal-title":"Mass Spectrom. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0755","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3851\/IMP1374","article-title":"Antiretroviral therapy in macrophages: implication for HIV eradication","volume":"20","author":"Gavegnano","year":"2009","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.bcp.2021.114893_b0760","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jconrel.2014.08.003","article-title":"Targeting strategies for delivery of anti-HIV drugs","volume":"192","author":"Ramana","year":"2014","journal-title":"J. Controlled Release: Official J. Controlled Release Soc."},{"key":"10.1016\/j.bcp.2021.114893_b0765","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejps.2015.04.011","article-title":"Improving bioavailability and biodistribution of anti-HIV chemotherapy","volume":"75","author":"Giacalone","year":"2015","journal-title":"Eur. J. Pharm. Sci.: Official J. Eur. Fed. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2021.114893_b0770","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3091","article-title":"Non-viral nucleic acid delivery to the central nervous system and brain tumors","volume":"21","author":"Wang","year":"2019","journal-title":"J Gene Med."},{"key":"10.1016\/j.bcp.2021.114893_b0775","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.phrs.2016.07.007","article-title":"Nanoparticle-mediated delivery of suicide genes in cancer therapy","volume":"111","author":"Vago","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2021.114893_b0780","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3390\/v7041578","article-title":"Eradication of HIV-1 from the macrophage reservoir: an uncertain goal?","volume":"7","author":"Abbas","year":"2015","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.bcp.2021.114893_b0785","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/QCO.0000000000000014","article-title":"Macrophages: the neglected barrier to eradication","volume":"26","author":"Watters","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.bcp.2021.114893_b0790","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2016.09.011","article-title":"Gene therapy for the CNS using AAVs: the impact of systemic delivery by AAV9","volume":"241","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0795","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/jnc.13861","article-title":"Trafficking of adeno-associated virus vectors across a model of the blood\u2013brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells","volume":"140","author":"Merkel","year":"2017","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.bcp.2021.114893_b0800","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1517\/14728214.2015.1041375","article-title":"Moving towards treatments for spinal muscular atrophy: Hopes and limits","volume":"20","author":"Wirth","year":"2015","journal-title":"Expert Opin. Emerging Drugs"},{"key":"10.1016\/j.bcp.2021.114893_b0805","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.biomaterials.2018.05.041","article-title":"Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration","volume":"176","author":"Zhang","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.bcp.2021.114893_b0810","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3390\/v13071205","article-title":"Harnessing the natural biology of adeno-associated virus to enhance the efficacy of cancer gene therapy","volume":"13","author":"Bower","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.bcp.2021.114893_b0815","doi-asserted-by":"crossref","unstructured":"A. Prashanth et al., Cancers systematic review are in vitro human blood-brain-tumor-barriers suitable replacements for in vivo models of brain permeability for novel therapeutics? (2021) doi: 10.3390\/cancers13050955.","DOI":"10.3390\/cancers13050955"},{"key":"10.1016\/j.bcp.2021.114893_b0820","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02759","article-title":"More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis","volume":"10","author":"Gschwandtner","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0825","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/1535-7163.MCT-14-0850","article-title":"Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models","volume":"14","author":"Peng","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"7540","key":"10.1016\/j.bcp.2021.114893_b0830","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature13989","article-title":"Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors","volume":"518","author":"Gomez Perdiguero","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bcp.2021.114893_b0835","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1517\/14712598.4.11.1757","article-title":"Gene therapy strategies to improve the effectiveness of cancer radiotherapy","volume":"4","author":"Freytag","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2021.114893_b0840","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/BF02893457","article-title":"Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect","volume":"12","author":"Lumniczky","year":"2006","journal-title":"Pathol. Oncol. Res."},{"issue":"11","key":"10.1016\/j.bcp.2021.114893_b0845","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1158\/1535-7163.MCT-09-0350","article-title":"Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy","volume":"8","author":"Martinez-Quintanilla","year":"2009","journal-title":"Mol. Cancer Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221005190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221005190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:13:25Z","timestamp":1762096405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221005190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":169,"alternative-id":["S0006295221005190"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114893","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suicide gene therapy in cancer and HIV-1 infection: An alternative to conventional treatments","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114893"}}